Fertility issues in survivors from adolescent cancers.

Abstract:

:Infertility is a common and distressing late-effect of cancer treatment. Whist sperm banking for post-pubertal males and embryo freezing for women (who are in a stable relationship at the time of treatment) are highly successful fertility preservation strategies, for females without a partner (including young and pre-pubescent girls) and pre-pubescent boys (or azoospermic men), there remain no effective approaches. Whilst the biological effects of cancer treatments on the reproductive system are well described, there are few data on the relative incidence of infertility (failure to conceive after one year of trying) in cancer survivors. This makes it difficult to advise survivors about their future fertility prospects. Whilst some will undoubtedly conceive naturally with their partner, others will require assisted conception treatment of which in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI) are the most common. Pregnancy outcomes of cancer survivors are generally good, although there is increased risk of pre-term birth and low birth-weight in the offspring of women who have received pelvic irradiation. There is no increased incidence of genetic disease or cancer incidence in the offspring of cancer survivors. Current research directions are focussing on alternative fertility preservation strategies including in vitro maturation techniques, xenotransplantation and the development of technology to create artificial gametes in the laboratory. Finally, although the reproductive techniques discussed are highly effective, country specific differences in the legal framework means that cancer survivors may be denied access to certain treatments (e.g. embryo cryopreservation) because they are forbidden by specific national legislation.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Pacey AA

doi

10.1016/j.ctrv.2007.02.001

subject

Has Abstract

pub_date

2007-11-01 00:00:00

pages

646-55

issue

7

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(07)00031-X

journal_volume

33

pub_type

杂志文章,评审
  • Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.

    abstract::Since its first regulatory approval more than 10 years ago, oncologists have gained wide experience in using the oral fluoropyrimidine, capecitabine, as monotherapy or in combination with other agents and the body of evidence supporting these approaches continues to grow. Alongside this increasing experience has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.06.003

    authors: Barrett-Lee P,Bidard FC,Pierga JY

    更新日期:2009-11-01 00:00:00

  • Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

    abstract::The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer treatment. Despite the excellent disease control with initial EGFR TKI therapy, acquired resistance is ubiquitous and remains a key chal...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.02.006

    authors: Lim SM,Syn NL,Cho BC,Soo RA

    更新日期:2018-04-01 00:00:00

  • The sentinel node negative axilla: is it a no-go zone?

    abstract::The technique of sentinel node biopsy (SNB) presents a great opportunity to reduce the morbidity of surgical treatment of breast cancer. Using either dye, isotope or a combination, after completing a learning process a sensitivity of 80-99% may be achieved. Most surgeons would aim for a sensitivity of 95% but this wil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1053/ctrv.2002.0251

    authors: Fentiman IS,Mansel RE

    更新日期:2002-02-01 00:00:00

  • To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review.

    abstract:BACKGROUND:The association between alcohol intake and breast cancer recurrence or development of second primary breast cancer in the survivor population is unclear. The aim of this systematic review was to evaluate the existing evidence to assess the extent to which alcohol consumption is associated with breast cancer ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.010

    authors: Simapivapan P,Boltong A,Hodge A

    更新日期:2016-11-01 00:00:00

  • The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets.

    abstract::Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancer cases and currently has an overall five-year survival rate of only 15%. Patients presenting with advanced stage NSCLC die within 18-months of diagnosis. Metastatic spread accounts for >70% of these deaths. Thus elucidation of the mechanistic basis of ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.10.001

    authors: Wood SL,Pernemalm M,Crosbie PA,Whetton AD

    更新日期:2014-05-01 00:00:00

  • Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

    abstract::Lung cancer represents the most common cause of brain dissemination. Oncogene-addicted (EGFR- and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized by a unique metastatic neurotropism resulting in a particularly high incidence of brain metastases. The goal of optimal brain metastases management is t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.10.011

    authors: Wrona A,Dziadziuszko R,Jassem J

    更新日期:2018-12-01 00:00:00

  • Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

    abstract:INTRODUCTION:Identification of membrane proteins expressed exclusively on tumor cells is a goal for cancer drug development. The receptor tyrosine kinase-like orphan receptor type 1 and 2 (ROR1/2), are type-I transmembrane proteins expressed in cancer but not in adult normal tissue. Here, we explore the prognostic role...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2019.05.006

    authors: Saleh RR,Antrás JF,Peinado P,Pérez-Segura P,Pandiella A,Amir E,Ocaña A

    更新日期:2019-07-01 00:00:00

  • New developments in arc radiation therapy: a review.

    abstract::Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rational...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.01.004

    authors: Palma DA,Verbakel WF,Otto K,Senan S

    更新日期:2010-08-01 00:00:00

  • Improving attribution of adverse events in oncology clinical trials.

    abstract::Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.04.004

    authors: George GC,Barata PC,Campbell A,Chen A,Cortes JE,Hyman DM,Jones L,Karagiannis T,Klaar S,Le-Rademacher JG,LoRusso P,Mandrekar SJ,Merino DM,Minasian LM,Mitchell SA,Montez S,O'Connor DJ,Pettit S,Silk E,Sloan JA,Stewar

    更新日期:2019-06-01 00:00:00

  • Developments in the systemic treatment of metastatic cervical cancer.

    abstract::Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remains a major concern for public health. Systemic treatment with cisplatin, either in combination with external beam irradiation for locally advanced disease, or as monotherapy for recurrent/metast...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.05.009

    authors: Mountzios G,Soultati A,Pectasides D,Pectasides E,Dimopoulos MA,Papadimitriou CA

    更新日期:2013-08-01 00:00:00

  • Beyond BRCA: new hereditary breast cancer susceptibility genes.

    abstract::Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.008

    authors: Economopoulou P,Dimitriadis G,Psyrri A

    更新日期:2015-01-01 00:00:00

  • Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.

    abstract::Peptide receptor radionuclide therapy (PRRT) is an important therapeutic option for somatostatin receptor (SSTR) positive metastatic and/or inoperable neuroendocrine tumours (NETs). However, in patients with poorly controlled carcinoid syndrome, it may lead to an acute flare of carcinoid symptoms or even carcinoid cri...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.03.002

    authors: Tapia Rico G,Li M,Pavlakis N,Cehic G,Price TJ

    更新日期:2018-05-01 00:00:00

  • Low dose cyclophosphamide: Mechanisms of T cell modulation.

    abstract::Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.11.005

    authors: Madondo MT,Quinn M,Plebanski M

    更新日期:2016-01-01 00:00:00

  • Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

    abstract::Biliary tract cancer is a quite rare disease; despite recent significant advances in imaging modalities, most of the patients have advanced disease at presentation thus making radical surgery not feasible. Many different chemotherapeutic regimens have been investigated in small uncontrolled studies, with generally dis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.03.003

    authors: Berardi R,Scartozzi M,Freddari F,Squadroni M,Santinelli A,Bearzi I,Fabris G,Cascinu S

    更新日期:2006-08-01 00:00:00

  • Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell.

    abstract::Haplo-identical transplant is being increasingly used in patients who do not have a readily available matched related or unrelated donor. Post-transplant cyclophosphamide's use due to its simplicity and documented efficacy has made this approach readily employable across diverse transplant centres across the globe. Th...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102071

    authors: Patil S,Potter V,Mohty M

    更新日期:2020-09-01 00:00:00

  • Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

    abstract::When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.007

    authors: Chargari C,Kirov KM,Bollet MA,Magné N,Védrine L,Cremades S,Beuzeboc P,Fourquet A,Kirova YM

    更新日期:2011-06-01 00:00:00

  • Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients.

    abstract::Patient-controlled analgesia (PCA) was administered in the domiciliary environment in 143 pre-terminally and terminally ill tumour patients suffering either from excruciating chronic pain or severe chronic/acute complex pain that could not be relieved adequately by oral analgesia. Morphine solutions were infused subcu...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/s0305-7372(96)90076-6

    authors: Meuret G,Jocham H

    更新日期:1996-01-01 00:00:00

  • Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.

    abstract::In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/s0305-7372(83)80013-9

    authors: Scheulen ME,Niederle N,Bremer K,Schütte J,Seeber S

    更新日期:1983-09-01 00:00:00

  • Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

    abstract::RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (cod...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.05.008

    authors: Hecht JR,Douillard JY,Schwartzberg L,Grothey A,Kopetz S,Rong A,Oliner KS,Sidhu R

    更新日期:2015-09-01 00:00:00

  • Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.

    abstract::Prostate cancer is androgen-dependent in its early stages and androgen deprivation therapy represents the most effective first-line therapeutic approach. However, after an initial remission, prostate cancer progresses towards the castration resistant prostate cancer (CRPC) stage, with increased malignancy and resistan...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.12.003

    authors: Limonta P,Manea M

    更新日期:2013-10-01 00:00:00

  • Early diagnosis and surgical management of prostate cancer.

    abstract::Prostate cancer is a significant cause of morbidity and mortality in the United States and Europe. The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00096-3

    authors: Linton KD,Hamdy FC

    更新日期:2003-06-01 00:00:00

  • Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.

    abstract::Although surgery provides excellent control for localized prostate cancer, pathologic examination of more than one-third of specimens will reveal positive surgical margins, seminal vesicle invasion, and/or extracapsular extension, thus putting these patients at increased risk of cancer recurrence. "Adjuvant" radiother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.07.001

    authors: Raldow A,Hamstra DA,Kim SN,Yu JB

    更新日期:2011-04-01 00:00:00

  • Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis.

    abstract:BACKGROUND:The immune system plays an important role in cancer pathogenesis. A low lymphocyte-to-monocyte ratio (LMR), as a simple biomarker of host immune system, has been suggested to be related to poor prognosis in various cancers. We performed a systematic review and meta-analysis to quantify the prognostic value o...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2015.10.003

    authors: Nishijima TF,Muss HB,Shachar SS,Tamura K,Takamatsu Y

    更新日期:2015-12-01 00:00:00

  • Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.

    abstract::We review radiation therapy (RT) options available for prostate cancer, including external beam (EBRT; with conventional fractionation, hypofractionation, stereotactic body RT [SBRT]) and brachytherapy (BT), with an emphasis on the outcomes, toxicities, and contraindications for therapies. PICOS/PRISMA methods were us...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.06.006

    authors: Zaorsky NG,Shaikh T,Murphy CT,Hallman MA,Hayes SB,Sobczak ML,Horwitz EM

    更新日期:2016-07-01 00:00:00

  • Prevention of chemotherapy and radiation toxicity with glutamine.

    abstract:GOALS OF THE WORK:Malignancy produces a state of physiologic stress that is characterized by a relative deficiency of glutamine, a condition that is further exacerbated by the effects of cancer treatment. Glutamine deficiency may impact on normal tissue tolerance to antitumor treatment, and may lead to dose reductions ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00133-6

    authors: Savarese DM,Savy G,Vahdat L,Wischmeyer PE,Corey B

    更新日期:2003-12-01 00:00:00

  • Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.

    abstract::The HER2 oncogene encodes a transmembrane protein partially homologous to epidermal growth factor receptor. This oncogene has been studied mainly in breast cancer where it has prognostic, predictive and therapeutic target value. The expression of HER2 in epithelial ovarian cancer has been less studied. HER2 expression...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.01.001

    authors: Serrano-Olvera A,Dueñas-González A,Gallardo-Rincón D,Candelaria M,De la Garza-Salazar J

    更新日期:2006-05-01 00:00:00

  • The expanding role of immunotherapy.

    abstract::The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landsc...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.01.008

    authors: Martin-Liberal J,Ochoa de Olza M,Hierro C,Gros A,Rodon J,Tabernero J

    更新日期:2017-03-01 00:00:00

  • Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

    abstract::Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients with locally advanced or metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.012

    authors: Custodio A,Puente J,Sastre J,Díaz-Rubio E

    更新日期:2009-12-01 00:00:00

  • Differential expression of drug resistance following in vitro exposure of human tumour cell lines to fractionated X-irradiation.

    abstract::We have established that drug resistance can be expressed following in vitro exposure of tumour cells not only to antitumor drugs but also to fractionated X-irradiation. These data therefore suggest a biological basis for the clinical problem of drug resistance that can occur in patients with previously irradiated tum...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(90)90012-5

    authors: Hill BT,Whelan RD,Hosking LK,Bedford P,Dempke WC,Shellard SA

    更新日期:1990-12-01 00:00:00

  • p53 as a target for the treatment of cancer.

    abstract::TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.004

    authors: Duffy MJ,Synnott NC,McGowan PM,Crown J,O'Connor D,Gallagher WM

    更新日期:2014-12-01 00:00:00